SYNRX THERAPEUTICS
SynRx Therapeutics produces medicines for cancer and concentrates on the development of novel drugs targeting the DNA damage repair pathway. They provide therapies for the patients fighting against cancer.
SYNRX THERAPEUTICS
Industry:
Biopharma Biotechnology Medical
Founded:
2021-08-01
Address:
Yuhang, Zhejiang, China
Country:
China
Website Url:
http://www.synrx-therapeutics.com
Total Employee:
51+
Status:
Active
Email Addresses:
[email protected]
Technology used in webpage:
Euro Pound Sterling Japanese Yen Hong Kong Server Location
Similar Organizations
Adept Biopharma
Adept Biopharma develops innovative immuno-therapeutics to help cancer patients.
Chimeron Bio
Chimeron Bio develops agents for personalized cancer gene therapy.
JSK Therapeutics
JSK Therapeutics is in order to develop new anti-cancer therapeutics
Lutris Pharma
Lutris Pharma develops drugs to improve anti-cancer therapy effectiveness.
Novamed
Novamed develops and manufactures diagnostic systems.
Peroxitech Therapeutics
Peroxitech Therapeutics operates as a biopharmaceutical company.
Tcino Bioscience
Tcino Bioscience develops molecule anti-cancer drugs for cancer patients.
Investors List
Longpan Investment
Longpan Investment investment in Seed Round - SynRx Therapeutics
Official Site Inspections
http://www.synrx-therapeutics.com
- Host name: 43.155.88.71
- IP address: 43.155.88.71
- Location: Japan
- Latitude: 35.69
- Longitude: 139.69
- Timezone: Asia/Tokyo
More informations about "SynRx Therapeutics"
SynRx Therapeutics
Using synthetic lethality strategy, SynRx Therapeutics is developing novel anti-cancer agents. Several first-in-class compounds are currently in preclinical studies. Founder . Xiaochun Yu . Professor, Founder and Chairman . …See details»
SynRx Therapeutics - Crunchbase Company Profile & Funding
Where is SynRx Therapeutics 's headquarters? SynRx Therapeutics is located in Yuhang, Zhejiang, China. Who invested in SynRx Therapeutics? SynRx Therapeutics is funded by …See details»
杭州圣域生物医药科技有限公司_官网 - SynRx
SynRx Therapeutics is an innovative R&D company focusing on the development of novel anti-tumor drugs using synthetic lethality approaches. We are currently exploring several first-in …See details»
SynRx Therapeutics - 2025 Company Profile - Tracxn
SynRx Therapeutics has raised a total funding of $14.2M over 1 round. Its latest funding round was a Seed round on Nov 16, 2022 for $14.2M. 4 investors …See details»
SynRx 2025 Company Profile: Valuation, Funding & Investors
SynRx General Information Description. Developer of a novel therapeutic approach intended for targeted drug delivery. The company's platform utilizes living microorganisms loaded with …See details»
SynRx
杭州圣域生物医药科技有限公司（SynRx Therapeutics）是一家专注在DNA损伤修复领域的创新药研发公司。 公司以西湖大学生命科学学院俞晓春教授为主要创始人，专注于靶向癌症化疗药物的研发。See details»
SynRx Therapeutics - PitchBook
SynRx Therapeutics General Information Description. Developer of innovative drugs designed for DNA damage repair (DDR). The company focuses on the development of novel anti-tumor drugs using synthetic lethality approaches, …See details»
SynRx Therapeutics - VentureRadar
SynRx Therapeutics is an innovative R&D company focusing on the development of novel anti-tumor drugs using synthetic lethality approaches. We are currently exploring several first-in …See details»
SynRx Therapeutics - Products, Competitors, Financials, Employees ...
About SynRx Therapeutics. SynRx Therapeutics is a drug research and development company focusing on the field of DNA damage repair. It develops anti-tumor drugs using synthetic …See details»
A Best-in-Class Polθ Inhibitor SYN818 from SynRx Therapeutics …
Aug 6, 2024 SynRx Therapeutics, a precision oncology company focused on DNA damage repair and synthetic lethality, announced that on July 24th, the U.S. Food and Drug …See details»
SynRx Therapeutics Co., Ltd. - Drug pipelines, Patents ... - Patsnap
Clinical Trials associated with SynRx Therapeutics Co., Ltd. CTR20244063 / Not yet recruiting Phase 1. ... The statistics for drugs in the Pipeline is the current organization and its …See details»
VBData reported：SynRx Therapeutics: Development of next …
Jan 8, 2022 SynRx Therapeutics is an innovative R&D company focusing on the development of novel anti-tumor drugs using synthetic lethality approaches. We are currently exploring several …See details»
SynRx Therapeutics - Funding, Financials, Valuation & Investors
Nov 16, 2022 Organization. SynRx Therapeutics . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. Highlights. Funding …See details»
SynRx Therapeutics | VentureRadar
SynRx Therapeutics is an innovative R&D company focusing on the development of novel anti-tumor drugs using synthetic lethality approaches. We are currently exploring several first-in …See details»
SynRx Therapeutics
Apr 7, 2024 Author：SynRx Therapeutics,LLC. Click： Time：2024-04-07 11:17:15 April 5, AACR Annual Meeting (AACR 2024) opened at the San Diego Convention Center, San Diego, …See details»
SY-005 (SynRx Therapeutics) - Drug Targets, Indications, Patents
OBJECTIVES: To evaluate the study design and feasibility of drug administration and safety in a randomized clinical trial of recombinant human annexin A5 (SY-005), a constitutively …See details»
SynRx Therapeutics presents data on the PARG inhibitor program …
Oct 24, 2024 SynRx Therapeutics announces the presentation of its PARG inhibitor program at the 36th EORTC-NCI-AACR Symposium taking place in Barcelona, Spain, on October 25, …See details»
SYN818 - Drug Targets, Indications, Patents - Synapse
SYN818: a POLQ inhibitors Drug, Initially developed by SynRx Therapeutics Co., Ltd., Now, its global highest R&D status is Phase 1, Mechanism: POLQ inhibitors(DNA polymerase theta …See details»
Pipeline details - synrx-therapeutics.com
Genomic instability is a hallmark of cancer cells, which is largely caused by DNA damage repair defects. Targeting DNA damage repair pathways increases additional burdens to cancer cells …See details»
SynRx Raises $14 Million to Develop Drugs for Solid Tumor …
On November 17, 2022 SynRx Therapeutics, a Hangzhou biopharma startup, reported that closed a $14 million Series Pre-A financing round to advance its portfolio of five oncology candidates …See details»